Note: Due to rising COVID-19 infections tied to the spread of SARS-CoV-2 variants, the U.S. Department of Defense (as the symposium sponsor) has cancelled the conference. The Company will be discussing with George Mason University scientists, who were scheduled to present Brilacidin research on non-SARS-CoV-2 viruses, appropriate next steps for potential release of these findings.

***

New antiviral research related to Brilacidin has been accepted for an Oral Presentation at the 2021 Military Health System Research Symposium (MHSRS), taking place August 23-26, 2021, at the Gaylord Palms Resort and Convention Center, Kissimmee, FL.

The Brilacidin presentation will be part of the “Development of New Front Line Therapies to Prevent and Treat Non-SARS-CoV-2 Endemic Viral Diseases” Breakout Session.

The MHSRS is an annual four-day scientific symposium sponsored by the U.S. Department of Defense. The presentation on Brilacidin will be part of the “Development of New Front Line Therapies to Prevent and Treat Non-SARS-CoV-2 Endemic Viral Diseases” Breakout Session.

Out of nearly 2,300 submissions, approximately 20 percent were accepted for presentation.